RxDoctor Payments DataLook up a doctor →

James Sublett, MD

Allergy & Immunology · Louisville, KYNPI 1255474136

Payments from drug & device makers

$1,737,589in general payments, 2019–2025

Across 937 payments — averaging $1854.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$568K
  • Biocryst Pharmaceuticals, Inc.$271K
  • Sanofi$159K
  • Amgen$118K
  • Novartis$88K
  • Regeneron Healthcare Solutions, Inc.$82K
  • plus $451K from 38 others

What the payments were for

  • Consulting fees$172,63129%
  • Speaking & faculty fees$354,67460%
  • Grants$2,7000%
  • Travel & lodging$38,1796%
  • Food & beverage$19,8333%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,737,589 in reported general payments places this provider in the 95th percentile of 66 allergy & immunology providers in Kentucky.

See all allergy & immunology providers in Kentucky

Medicare billing

Part B allowed, 2024
$369,383
Medicare patients
390
Services billed
22,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$48,078
Breo ElliptaFluticasone/Vilanterol35$15,898
Epinephrine60$14,708
Spiriva RespimatTiotropium Bromide13$8,889
DuleraMometasone/Formoterol12$8,869
SymbicortBudesonide/Formoterol Fumarate18$7,207
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,180
Advair HfaFluticasone Propion/Salmeterol12$3,698
Azelastine Hcl129$3,365
Azelastine-FluticasoneAzelastine/Fluticasone11$3,219
BreynaBudesonide/Formoterol Fumarate24$2,905
Albuterol Sulfate HfaAlbuterol Sulfate65$2,363
Fluticasone Propionate173$2,215
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,327
Ipratropium Bromide43$1,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$29,989$63,97588 claims
Hikma Pharmaceuticals USAEpinephrine$4,345$14,70860 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$54$14,06924 claims
MerckDulera$18$8,86912 claims
AstraZenecaSymbicort$567,640$7,20718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 66 allergy & immunology providers in Kentucky.

Other allergy & immunology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →